Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
NASH - Nonalcoholic SteatohepatitisThis is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of concomitant administration of itraconazole or rifampin on the pharmacokinetics and safety of EDP-305 in healthy human volunteers.
6-week Safety and PD Study in Adults With NAFLD
Non-alcoholic Fatty Liver DiseaseIN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSESSED IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
NASH - Nonalcoholic SteatohepatitisNAFLD1 moreA multi-centre randomised controlled trial to determine the implementation and health care cost of LiverMultiScan vs. routine methodical assessment (standard care) of Non-alcoholic fatty liver disease (NAFLD) across several European countries.
A Clinical Trial to Evaluate the Efficacy and Safety of MXP22 on Liver Health
Non-Alcoholic Fatty Liver DiseaseA randomized, double blind, placebo controlled clinical trial to evaluate the efficacy and safety of MXP22 on liver health
Hepatic Inflammation and Physical Performance in Patients With NASH
Non-alcoholic Fatty Liver DiseaseThe aim of the study is to examine the influence of hepatic inflammation or damage on physical performance (maximal oxygen uptake, VO2max) depending on the histologic state of the liver. The study population are patients with fatty liver disease and non-alcoholic steatohepatitis (NASH). All study participants obtain an individual training plan with individual and group training sessions for a period of 8 weeks. At the beginning and end of the training phase a sport physiological examination is carried out. In the study group the effect of regular examinations is surveyed by surrogate parameters of liver inflammation.
A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose
Non-Alcoholic SteatohepatitisThe purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.
The Effect of an RBAC Supplement (BRM4) on NAFLD
Non-Alcoholic Fatty Liver DiseaseThe purpose of this study is to investigate the effects of Rice Bran Arabinoxylan Compound (RBAC) on outcome variables in persons with non-alcoholic fatty liver disease (NAFLD). This nutritional supplement is made from a water soluble extract of rice bran that has been partially hydrolyzed by the action of a natural enzyme complex extracted from Shiitake mushroom.
Magnetic Resonance Imaging (MRI) Fat Quantification of the Liver
Non-alcoholic Fatty Liver DiseaseObesityFatty liver in the obese is a common finding; some cases develop steato-hepatosis which in the long-term can lead to liver cirrhosis. The effect of bariatric surgery on fat distribution in the liver has so far been studied with liver biopsies and single voxel MR techniques. With this trial investigators present a new, whole organ MR-quantification of liver fat and describe changes after bariatric surgery in visceral and subcutaneous fat.
Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic Syndrome
Non-alcoholic Fatty LiverMetabolic SyndromeThis study is conducted to investigate if vitamin E status in healthy individuals and individuals with metabolic syndrome can be improved by dairy fat. The investigators hypothesize that full-fat dairy will substantially increase the bioavailability of alpha-tocopherol, a form of vitamin E. The results of this study will contribute to the application of dairy fat as a simple and effective strategy for improving vitamin E status, which is partly due to poor vitamin E intake. By completing this study, the investigators anticipate developing new dietary recommendations to achieve adequate vitamin E status through the regular consumption of dairy fat paired with foods containing vitamin E.
The Effects of PXR Activation on Hepatic Fat Content
Non-alcoholic Fatty Liver DiseaseThis study investigates the effects of pregnane X receptor (PXR) activation on hepatic fat content in healthy volunteers. Rifampicin (an antibiotic and also an efficient PXR activator) and placebo will be given for a week to volunteers. Hepatic fat content is measured with magnetic resonance imaging and blood samples are collected at the end of each study arm. The investigators' hypothesis is that rifampicin causes accumulation of fat to the liver.